Xencor, Inc Cash and Cash Equivalents
Xencor, Inc (XNCR) had Cash and Cash Equivalents of $44.66 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-05
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $44.66M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $14.17M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $54.07M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $28.29M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $44.66M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $14.17M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $54.07M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $28.29M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $44.44M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $39.67M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $40.88M 10-K · filed 2026-02-25 |
| 2024-09-30 | $29.03M 10-Q/A · filed 2025-02-24 |
| 2024-06-30 | $30.77M 10-Q/A · filed 2025-02-24 |
| 2024-03-31 | $31.03M 10-Q/A · filed 2025-02-24 |
| 2023-12-31 | $53.79M 10-K · filed 2025-02-27 |
| 2023-09-30 | $52.73M 10-Q/A · filed 2025-02-24 |
| 2023-06-30 | $34.71M 10-Q/A · filed 2025-02-24 |
| 2023-03-31 | $72.39M 10-Q/A · filed 2025-02-24 |
| 2022-12-31 | $53.94M 10-K · filed 2025-02-27 |
| 2022-09-30 | $52.65M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $49.41M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $78.27M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $143.48M 10-K · filed 2023-02-27 |
| 2021-09-30 | $41.20M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $115.84M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $176.97M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $163.54M 10-K · filed 2022-02-24 |
| 2020-09-30 | $58.09M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $109.53M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $73.81M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $50.31M 10-K · filed 2021-02-24 |
| 2019-09-30 | $51.19M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $32.56M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $21.86M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $26.25M 10-K · filed 2020-02-25 |
| 2018-09-30 | $35.00M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $35.29M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $251.57M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $16.53M 10-K · filed 2019-02-26 |
| 2017-09-30 | $13.63M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $11.22M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $13.56M 10-Q · filed 2018-05-07 |
| 2016-12-31 | $14.53M 10-Q · filed 2018-05-07 |
| 2016-09-30 | $14.79M 10-Q · filed 2017-11-08 |
| 2016-06-30 | $7.88M 10-Q · filed 2017-08-07 |
| 2016-03-31 | $8.15M 10-Q · filed 2017-05-10 |
| 2015-12-31 | $12.59M 10-K · filed 2018-02-28 |
| 2015-09-30 | $57.74M 10-Q · filed 2016-11-02 |
| 2015-06-30 | $11.17M 10-Q · filed 2016-08-03 |
| 2015-03-31 | $119.05M 10-Q · filed 2016-05-02 |
| 2014-12-31 | $54.65M 10-K · filed 2018-02-28 |
| 2014-09-30 | $60.92M 10-Q · filed 2015-11-04 |
| 2014-06-30 | $66.22M 10-Q · filed 2015-08-05 |
| 2014-03-31 | $72.54M 10-Q · filed 2015-05-05 |
| 2013-12-31 | $77.97M 10-K · filed 2017-03-01 |
| 2013-09-30 | $9.62M 10-Q · filed 2014-11-10 |
| 2013-06-30 | $11.75M 10-Q · filed 2014-08-01 |
| 2013-03-31 | $3.41M 10-Q · filed 2014-05-15 |
| 2012-12-31 | $2.31M 10-K · filed 2016-03-08 |
| 2011-12-31 | $14.54M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |